Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Authors
Ruzsa, ASen, M
Evans, M
Lee, Lip W
Hideghety, K
Rottey, S
Klimak, P
Holeckova, P
Fayette, J
Csoszi, T
Erfan, J
Forssmann, U
Goddemeier, T
Bexon, A
Nutting, C
Affiliation
Zala Megyei Kórház Külsokórház Onkológia Osztály, Zalaegerszeg, Pozva, HungaryIssue Date
2014-12
Metadata
Show full item recordAbstract
To determine whether EMD 1201081, a TLR9 agonist, added to cetuximab had antitumor activity in second-line recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).Citation
Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). 2014, 32 (6):1278-84 Invest New DrugsJournal
Investigational New DrugsDOI
10.1007/s10637-014-0117-2PubMed ID
24894651Type
ArticleLanguage
enISSN
1573-0646ae974a485f413a2113503eed53cd6c53
10.1007/s10637-014-0117-2